英菲格拉替尼能延长患者的生存期吗？有哪些不良反应

Infigratinib is a small molecule ATP-competitive tyrosine kinase inhibitor of FGFR that blocks downstream signaling cascades by selectively binding and inhibiting FGFR activity. Infigratinib induces tumor cell death by reducing cancer cell proliferation. Can that extend patient survival?

A multi-center, single-group clinical study enrolled a total of 71 subjects. The drug mainly evaluated the efficacy of Infigratinib as a third-line or above treatment for patients with FGFR2 fusion-positive cholangiocarcinoma. The results showed that in the case of second-line treatment, the median progression-free survival (PFS) of patients was 4.63 months; the median PFS of patients who received third-line or above treatment with Infigratinib was 6.77 months, and the objective response rate (ORR) of patients who received third-line or above treatment was 21.6%. It can be seen from the above test results that infigratinib can prolong the survival period of patients, increase the remission rate, improve the quality of life of patients, reduce the pain of patients, and have a positive effect on the patient's condition. However, patients cannot blindly use this drug for treatment, because the use of infigratinib will also produce some adverse reactions.

What are the adverse reactions of infigratinib?

Adverse reactions of infigratinib include: nail toxicity, stomatitis, dry eye, fatigue, alopecia, palmoplantar erythema syndrome, joint pain, dysgeusia, constipation, abdominal pain, dry mouth, eyelash changes, diarrhea, dry skin, loss of appetite, blurred vision, vomiting, etc. If a patient has a serious adverse reaction during treatment with Infigratinib, he or she should go to the hospital immediately and receive formal treatment from a professional doctor. Patients cannot blindly use other drugs for treatment to avoid more adverse reactions.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: